FOR IMMEDIATE RELEASE
Press Contact:
Cerexa‚ Inc.
Stan Abel
Phone: 510–747–3911
seabel@cerexa.com
Press Contact:
Noonan Russo
David Schull
Phone: 858–546–4810
david.schull@eurorscg.com
Cerexa to Present at Credit Suisse Biotechnology Conference
ALAMEDA‚ Calif.‚ September 18‚ 2006 – Cerexa, Inc. today announced that Dennis Podlesak, Chief Executive Officer, will present at the Credit Suisse Biotechnology Conference on September 19, 2006 in Boston, MA. Mr. Podlesak will provide a brief corporate overview and discuss the company’s lead product candidate, Ceftaroline, including positive top-line results from the recently completed Phase 2 study of Ceftaroline for the treatment of complicated skin infections.
About Ceftaroline
Ceftaroline acetate is a member of the cephalosporin class of antibiotics‚ the most frequently prescribed class of antibiotics in the world. In preclinical studies and clinical trials to date‚ Ceftaroline demonstrated a favorable safety profile‚ similar to that of existing cephalosporins. Unlike marketed cephalosporins‚ Ceftaroline exhibits bactericidal activity against the most resistant strains of gram–positive bacteria‚ including methicillin–resistant Staphylococcus aureus (MRSA). Ceftaroline has also demonstrated bactericidal activity against penicillin–resistant Streptococcus pneumoniae and common gram–negative bacteria. Cerexa licensed from Takeda Pharmaceutical Company Limited the exclusive right to develop and commercialize Ceftaroline in all countries worldwide except Japan.
About Cerexa
Cerexa Inc. is an innovation-driven biopharmaceutical company focused on discovering, developing and commercializing a growing portfolio of novel anti-infective therapies for the treatment of serious, antibiotic-resistant infections. For more information, visit www.cerexa.com.